What if you had a tool to change the genetic instructions that cause disease?
That’s what San Francisco-based Scribe Therapeutics hopes to do with its next-generation platform for gene editing.
Today, the company announced a collaboration with Biogen to develop CRISPR-based genetic medicines for neurological diseases, including Amyotrophic Lateral Sclerosis (ALS).
CRISPR, you may remember, is a powerful tool used to control the genes (or genetic instructions) that are active in plants, animals, and even humans. With CRISPR gene editing, researchers can “silence” undesirable traits, and, potentially, add desirable traits.
Over the past few years, CRISPR gene editing has been used to reduce the severity of genetic deafness and treat sickle-cell anemia in mice. Today, CRISPR is considered
We are both physician-scientists at the University of Virginia. We care for COVID-19 patients and conduct research to find better ways to diagnose and treat COVID-19.
Here we are sharing what physicians have learned over the past eight months treating various stages of this disease. Early in the year, there were few known treatments for people who showed severe COVID-19 symptoms apart from sustaining them on ventilators. Now, several months later, there are a handful of treatments, including drugs, that give doctors far better tools to heal patients, particularly very ill ones.